PROPEL™ is an FDA‑cleared, steroid‑eluting sinus implant that self‑expands to maintain airway patency after functional endoscopic sinus surgery. It delivers a controlled dose of mometasone furoate from a bioresorbable polymer matrix that degrades in 30–45 days, eliminating the need for removal and reducing postoperative inflammation and polyp recurrence.
Funding
$1.8B raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients undergoing functional endoscopic sinus surgery often experience post‑operative inflammation and restenosis, leading to reduced sinus patency and delayed mucociliary clearance. Conventional packing materials provide mechanical support but lack targeted drug delivery, resulting in suboptimal control of chronic rhinosinusitis symptoms.
Solution
PROPEL™ is an FDA‑cleared, steroid‑eluting sinus implant designed for placement immediately after sinus surgery. The device self‑expands to conform to the sinus cavity, maintaining airway openness while delivering a controlled dose of mometasone furoate directly to the mucosa. Its bio‑resorbable polymer matrix degrades over 30–45 days, eliminating the need for removal and allowing natural mucociliary function to resume. By combining mechanical scaffolding with localized anti‑inflammatory therapy, PROPEL™ reduces postoperative edema, lowers the risk of polyp recurrence, and shortens recovery time. The implant integrates seamlessly into standard surgical workflows and is compatible with existing endoscopic instruments.
Target Audience
Primary customers are otolaryngologists and ENT surgical centers performing functional endoscopic sinus surgery, as well as hospital systems seeking to improve postoperative outcomes for chronic rhinosinusitis patients.
Features
- Self‑expanding nitinol frame that adapts to variable sinus anatomy for consistent patency
- Bioresorbable polymer carrier loaded with 0.5 mg mometasone furoate for sustained local corticosteroid release
- FDA‑approved 30‑day and 45‑day degradation profiles that align with typical mucociliary clearance timelines
- Sterile, single‑use packaging compatible with standard endoscopic sinus surgery kits
- Radiopaque markers for intra‑operative visualization and postoperative imaging verification
- Proven safety and efficacy data from multicenter clinical trials in chronic rhinosinusitis patients
- Seamless integration with existing postoperative care protocols, eliminating the need for manual packing removal